Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records

Daniela Fonseca de Freitas1,2· India Patel1 · Giouliana Kadra-Scalzo1 · Megan Pritchard1,3 · Hitesh Shetty3 · Matthew Broadbent3 · Rashmi Patel1,3 · Johnny Downs1,3 · Aviv Segev1,4,5 · Mizanur Khondoker6 · James H. MacCabe1,3 · Kamaldeep Bhui2,7 · Richard D. Hayes1

Received: 4 October 2021 / Accepted: 18 February 2022 / Published online: 4 March 2022
© The Author(s) 2022

Abstract

Purpose Clozapine is the most effective intervention for treatment-resistant schizophrenia (TRS). Several studies report ethnic disparities in clozapine treatment. However, few studies restrict analyses to TRS cohorts alone or address confounding by benign ethnic neutropenia. This study investigates ethnic equity in access to clozapine treatment for people with treatment-resistant schizophrenia spectrum disorder.

Methods A retrospective cohort study, using information from 11 years of clinical records (2007–2017) from the South London and Maudsley NHS Trust. We identified a cohort of service-users with TRS using a validated algorithm. We investigated associations between ethnicity and clozapine treatment, adjusting for sociodemographic factors, psychiatric multi-morbidity, substance misuse, neutropenia, and service-use.

Results Among 2239 cases of TRS, Black service-users were less likely to be receive clozapine compared with White British service-users after adjusting for confounders (Black African aOR = 0.49, 95% CI [0.33, 0.74], p = 0.001; Black Caribbean aOR = 0.64, 95% CI [0.43, 0.93], p = 0.019; Black British aOR = 0.61, 95% CI [0.41, 0.91], p = 0.016). It was additionally observed that neutropenia was not related to treatment with clozapine. Also, a detention under the Mental Health Act was negatively associated clozapine receipt, suggesting people with TRS who were detained are less likely to be treated with clozapine.

Conclusion Black service-users with TRS were less likely to receive clozapine than White British service-users. Considering the protective effect of treatment with clozapine, these inequities may place Black service-users at higher risk for hospital admissions and mortality.

Keywords Refractory psychosis · Clozapine · Benign ethnic neutropenia · Black British · Asian British · Health inequalities
Background

Studies show ethnic inequalities in healthcare. For instance, ethnic minorities received poorer analgesic care [1] and reported worse experiences in maternal and in cancer care [2, 3]. Among people with a common mental disorder, compared to White British people, ethnic minorities are less likely to receive effective treatment [4], less likely to be referred to secondary care by their general practitioner (GP), and more likely to be referred to inpatient or emergency services [5]. A similar pattern in the pathway to care in psychosis is observed, with some ethnic minority groups having lower GP involvement and more compulsory admission [6]. Moreover, Black people are less likely to receive psychotherapies (cognitive behaviour/ family therapy), and are more likely to receive a long-acting injectable antipsychotic [7, 8].

Treatment-resistant schizophrenia (TRS) is defined as a failure to respond to two trials of antipsychotics with an adequate dose [9] and affects up to a third of people living with schizophrenia [10]. Clozapine is the recommended antipsychotic for TRS [11], producing superior outcomes than other antipsychotics in symptom response, user satisfaction [12, 13], hospitalisation [14, 15], and mortality [16, 17]. Some studies, including a systematic review, show that Black people are less likely to receive this drug [7, 16, 18–25]. However, not all studies report ethnic differences in clozapine prescription [26, 27], and mixed findings are observed even in studies conducted in the same region, such as London [16, 21, 26, 27].

Clinicians and minority ethnic service-users may resist clozapine treatment because of benign ethnic neutropenia (BEN). This is a condition of low baseline level of white cells that is more common in people of African, Arabian, and Mediterranean background [28, 29]. Clozapine-induced lowering of white cells (agranulocytosis) and related death is extremely rare [30], and the presence of BEN does not necessarily prevent the treatment with clozapine [28]. However, clozapine can only be prescribed after haematological consultation to assess neutropenia and a white cell count monitoring protocol. The presence of BEN could act as a barrier to clozapine treatment in Black people, but this has not been empirically tested. Other limitations of previous studies include the lack of a cohort of people with TRS (with the risk of confounding by indication) [23, 26], or cohorts of only inpatients or outpatients (restricting the generalisability of findings) [21, 26].

This study addresses these limitations by investigating ethnic disparities in the prescription of clozapine in a cohort of people with TRS, while adjusting for several potential confounders, including sociodemographic information, psychiatric multi-morbidity, substance misuse, service-use, and neutropenia. Our hypothesis is that ethnic minority services-users, specially Black people, are less likely to be treated with clozapine than their White British counterparts.

Methods

Setting and data sources

In this retrospective cohort study, we used data from the electronic health records (EHRs) of the South London and Maudsley (SLaM) National Health Service (NHS) Foundation Trust. SLaM’s catchment area comprises four London boroughs (Southwark, Lewisham, Lambeth, and Croydon), with a population of 1.3 M (2018 estimates). Access to the information to SLaM’s clinical records is made via the Clinical Record Interactive Search system (CRIS) established in 2007–2008 [31, 32]. At the time of writing, CRIS enabled access to the de-identified information, in the free-text and structured fields, of over 400,000 service-users. Multiple Natural Language Processing (NLP) applications are used to retrieve information on the free-text fields [31–34]. These applications outperform simple keyword searches, by identifying conditions of interest while distinguishing them from situations where related words are mentioned but are not the condition of interest [32, 34].

Moreover, CRIS provides several data linkages to national registries, including the Zaponex Treatment Access System (ZTAS) [16]. The ZTAS registry is the monitoring system for clozapine treatment used at SLaM (due to an exclusive license for the use of Zaponex). The monitoring system aims to prevent negative outcomes of clozapine-induced agranulocytosis and record-related relevant conditions, such as BEN. At the time of project conception, CRIS had a linkage enabling access to ZTAS data up to 31/03/2016.

CRIS was established under a robust data protection and governance framework and received approval from the Oxford C Research Ethics Committee (18/SC/0372) to be used as a de-identified dataset for secondary data analysis [31, 32]. This project was approved by the service user-led CRIS oversight committee.

Sample inclusion criteria

The sample comprises SLaM service-users who met the following inclusion criteria: (1) had a primary diagnosis of a schizophrenia spectrum disorder (ICD-10: F20–F29), (2) were taking antipsychotics between 1 January 2007 and 31 December 2017, (3) lived in the SLaM catchment or were homeless, (4) were 18 years or older at the time of that first
antipsychotic after 2007, and (5) met a proxy definition for treatment resistance, via a validated algorithm.

**Ascertainment of treatment resistance**

TRS was identified in an automated way, via the development and validation of several algorithms against a gold-standard, manually coded, dataset of TRS cases in a previous study [35]. In line with recommendations [9, 11], the coding rules for the ascertainment of TRS for the gold-standard dataset were evidence of (1) failure to respond to two 6-week trials of different antipsychotics or (2) clozapine prescription. Failure of response was assumed when the switch of the antipsychotic was not a result of non-adherence or adverse side-effects.

The algorithms developed to identify TRS in a large dataset were based on an automatic coding of trials of antipsychotic treatment and episodes of hospitalisation [11, 16]. An antipsychotic trial was defined by evidence of at least two prescriptions of the same antipsychotic, at least 6 weeks apart. To ensure that we did not exclude polypharmacy, which could be a switch from one antipsychotic to another, the first prescription of a new antipsychotic could take place at any point after the prescription of the previous and not only 6 weeks after. We selected the algorithm which performed best based on its precision (i.e., positive predictive value) and recall (i.e., sensitivity). More information on the algorithms is presented in the Supplementary Material Table S1. With the selected algorithm, the proxy definition for TRS was evidence of six trials of different antipsychotic drugs, clozapine prescription, or ZTAS registration. This algorithm provided good precision (84%) and recall (73%) against the gold-standard dataset. TRS date was assigned to the earliest occurrence of any of the three criteria for TRS.

**Measures**

Clozapine prescription between 1 January 2007 and 31 December 2017 (the study’s outcome), as well as information regarding the antipsychotic treatments used in the TRS algorithms, was retrieved using NLP applications [32, 33]. The applications identified antipsychotics by their generic and brand names. To increase reliability, antipsychotics had to be accompanied by dosage, but no minimum dose was established.

Ethnicity was based on the 16 ethnic categories used by the NHS, which were aggregated into eight categories due to small sample sizes. These were: (1) White British; (2) Other White [Irish and Other White background]; (3) Black African [Black African and White and Black African]; (4) Black Caribbean [Black Caribbean and White and Black Caribbean]; (5) Black British or Other Black background; (6) South Asian [Bangladeshi, Indian and Pakistani]; (7) Asian British or Other Asian [Chinese, White and Asian, and Other Asian background]; and (8) Other Ethnicity [Other Mixed background and any Other ethnicity].

Potential confounders included sociodemographic information, psychiatric diagnoses, substance misuse, other clinical and functional status factors, evidence of neutropenia (including benign ethnic neutropenia), and information regarding service-use. Sociodemographic confounders included gender, age at the date of TRS, homelessness ever before TRS, and neighbourhood deprivation. The latter was the index of multiple deprivation of the English Indices of Deprivation [36] assigned to the service-user’s address at TRS date.

Psychiatric diagnoses included the schizophrenia spectrum diagnosis and psychiatric comorbidities. Considering the possibility of multiple diagnoses within the schizophrenia spectrum being mentioned in clinical records at TRS date, the diagnoses were categorised according to the highest hierarchy: schizoaffective disorder (F25), schizophrenia (F20) or other diagnoses (F21–F24, F28–F29). Psychiatric comorbidities reported at any time before the TRS date comprised: (1) developmental disorders [developmental disorder, including autism (F80–F84), intellectual disability (F70–F79) or attention (F90)]; (2) anxiety-related disorders [anxiety (F40–F41), obsessive–compulsive (F42–F43), and post-traumatic stress (F43.1)], (3) bipolar (F30–F31, F34), (4) depression or other mood disorders excluding bipolar (F32–F39), and (5) personality disorder (F60–F61).

Evidence of substance misuse comprised having ever been diagnosed with any substance use-related disorder (F10–F14, F16, F18–F19) and previous use of cannabis. Cannabis use was identified using an NLP application [33, 37]. Other clinical, social, and functional factors were assessed using the 12 items of the Health of the Nation Outcomes Scales (HoNOS) [38]. Information was retrieved from the closest HoNOS to TRS date, but within one year before. The ratings were collapsed from five categories into 0 (not a problem) and 1 (a problem of any severity).

Given that a proportion of patients with neutropenia will be classified as having benign ethnic neutropenia (BEN), in this study, patients with BEN were included together with other patients who had evidence of neutropenia. Neutropenia was assumed when there were low neutrophil counts (<2.2 × 10⁹/L) in SLaM or ZTAS records, on two separate occasions at least 1 month apart. Information regarding BEN was retrieved from ZTAS sociodemographic information; thus, data on BEN were only available for service-users with records on ZTAS. No evidence of BEN or neutropenia, or no information on neutrophil counts, was coded as lack of evidence of neutropenia. Information on evidence of neutropenia was retrieved up to the point of clozapine prescription or the end of the observation window.
Service-use measures comprised: number of days of hospitalisation within the 3 months prior to TRS date; number of days on which service-users had face-to-face contacts with outpatient teams in the 3 months prior to the TRS date; and if the service-users were detained to receive care under the Mental Health Act 1983 [39] at any time before TRS. We included civil involuntary hospitalisation under Part 2 of the Act, detention under police use of power, and forensic detentions under Part 3 of the Act.

**Statistical analysis**

Descriptive information and the relationships between ethnicity and the covariates are presented along with chi-squared analyses or analyses of variance (ANOVA). Logistic regression analyses were performed to investigate the association between ethnicity and clozapine prescription, controlling for each category of possible confounders. A fully adjusted model is presented, considering the number of covariates. Statistical analyses were conducted using STATA 15 [40].

**Results**

**Participants**

The sample comprises 2239 people meeting the inclusion criteria for TRS. Only 0.3% of participants were excluded because of missing ethnicity data. Service-users’ age was 18–90 years ($M = 40.9$, SD = 12.6) and 64% were men. Ethnic composition was: 32% were White British; 18% were Black Caribbean; 17% were Black British; 16% were Black African; 7% were from Other White background; 4% were Asian British, and 3% were South Asian (Table 1). The proportion of people across the various ethnic groups in the algorithm based TRS sample was similar to one observed in the manually coded TRS cohort.

**Sociodemographic and clinical characteristics of the TRS cohort by ethnicity**

We observed significant ethnic differences in the sociodemographic and clinical characteristics of people with TRS (Table 2). To mention a few, Black African and Black British people were aged between 36 and 37, whereas the mean age for Black Caribbean, White and Asian people was higher (41–43 years). Homelessness was more common in the Other White (16%) and Black African (13%) people.

White British people were more frequently diagnosed with comorbid mood (excluding bipolar) and personality disorders (18% and 17%, respectively). A substance use disorder was less frequent in South Asian people (<5%). Cannabis use was less common in White British (55%) and South Asian people (41%) and more common in the Black Caribbean (70%) and Black British people (76%). According to HoNOS ratings, hallucinations were less common in Black Caribbean people (76%), and depressed mood was more common in Other ethnicity (75%).

As expected, there were major differences in the proportion of people with evidence of neutropenia (including BEN), with the highest levels among Black African (15%), Black British (12%), Black Caribbean people (7%) and lower in the White British (2%). Analyses revealed a 3 to 8 fold higher relative odds for neutropenia among these ethnic groups, compared with the White British: ORBlack African = 8.45, 95% CI [4.69, 15.20], $p < 0.001$; ORBlack British = 6.64, 95% CI [3.65, 12.07], $p < 0.001$, ORBlack Caribbean = 3.76, 95% CI [1.99, 7.10], $p < 0.001$. The relative risk was not meaningfully calculated for other ethnic groups due to the small number of people with neutropenia (Table 2).

An episode of involuntary hospitalisation under the MHA Part 2 was more frequent among Black African (66%) and Black British (59%), than White British people (38%). Police detention was more common among Black African (26%) and less frequent in White British people (11%).

**Ethnicity and clozapine treatment**

In this cohort of people with TRS, 75% of the Black African people, 89% of the South Asian and 87% of White British people received clozapine (Table 1). Results from the logistic regression analyses (Table 3) show that when compared to the White British people (reference), Black African people were half as likely to receive clozapine (aOR = 0.49, 95% CI [0.33, 0.74], $p = 0.001$). Black Caribbean and Black British or Other Black people also less likely to receive clozapine (aOR$_{Black Caribbean}$ = 0.64, 95% CI [0.43, 0.93], $p = 0.019$; aOR$_{Black British/Black Other}$ = 0.61, 95% CI [0.41, 0.91], $p = 0.016$). These results were adjusted for sociodemographics, psychiatric diagnoses, substance misuse, evidence of neutropenia, and type and frequency of service-use. No significant differences were observed for other ethnicities (Other White background or Asian background and any Other ethnicity). In the models adjusting only for the HoNOS items regarding symptoms and impairment, which due to substantial missing data were not included in the fully adjusted model, there were lower rates of clozapine treatment among Black African and Black Caribbean people. Sensitivity analyses, restricting the cohort to people who met the proxy criteria for TRS before the end date of the CRIS data linkage with ZTAS (31/03/2016), revealed similar findings to the fully adjusted model with the all cohort (results on Supplementary Material, Table S2).
Table 1  Demographic and clinical characteristics of people with treatment-resistant schizophrenia

| Sample characteristics | Total: n (% of total sample) | Prescribed clozapine: n (% per characteristic) |
|------------------------|------------------------------|-----------------------------------------------|
| Total                  | 2239 (100)                  | 1837 (82.1)                                   |
| **Ethnicity**          |                              |                                              |
| White British          | 719 (32.1)                  | 628 (87.3)                                    |
| Black Caribbean        | 391 (17.5)                  | 303 (77.5)                                    |
| Black British/other Black background | 371 (16.6) | 296 (79.8)                                    |
| Black African          | 354 (15.8)                  | 267 (75.4)                                    |
| Other White background | 150 (6.7)                   | 128 (85.3)                                    |
| Other ethnic background| 109 (4.9)                   | 92 (84.4)                                     |
| Asian British/other Asian background | 84 (3.8) | 69 (82.1)                                     |
| South Asian            | 61 (2.7)                    | 54 (88.5)                                     |
| **Sociodemographic factors** |                        |                                              |
| Gender                 |                              |                                              |
| Men                    | 1438 (64.2)                 | 1221 (84.9)                                   |
| Women                  | 801 (35.8)                  | 616 (76.9)                                    |
| Age: M (SD)            | 40.9 (16.6)                 | 40.2 (12.3)                                   |
| Ever homeless before TRS date | 214 (9.6) | 130 (60.8)                                   |
| Neighbourhood deprivation score (6.7% missing)a: M (SD) | 31.6 (9.2) | 31.5 (9.3)                                   |
| **Primary diagnosis**  |                              |                                              |
| Schizophrenia          | 1611 (72.0)                 | 1350 (83.8)                                   |
| Schizoaffective disorder | 412 (18.4) | 300 (72.8)                                   |
| Other prolonged psychosis | 216 (9.7) | 187 (86.6)                                   |
| **Psychiatric comorbidities** |                       |                                              |
| Developmental disorder |                              |                                              |
| No                     | 2083 (93.0)                 | 1771 (82.1)                                   |
| Yes                    | 156 (6.8)                   | 126 (80.8)                                    |
| Anxiety-related disorder |                              |                                              |
| No                     | 2124 (94.9)                 | 1752 (82.5)                                   |
| Yes                    | 115 (5.1)                   | 85 (73.9)                                     |
| Bipolar disorder       |                              |                                              |
| No                     | 1891 (84.5)                 | 1612 (85.3)                                   |
| Yes                    | 348 (15.5)                  | 225 (64.7)                                    |
| Depression or other mood disorder (excluding bipolar) | 1889 (84.4) | 1568 (83.0)                                   |
| Yes                    | 350 (15.6)                  | 269 (76.9)                                    |
| Personality disorder   |                              |                                              |
| No                     | 1961 (87.6)                 | 1631 (83.2)                                   |
| Yes                    | 278 (12.4)                  | 206 (74.1)                                    |
| **Substance misuse**   |                              |                                              |
| Any substance use-related disorder | 1954 (87.3) | 1639 (83.9)                                   |
| Yes                    | 285 (12.7)                  | 198 (69.5)                                    |
| Evidence of cannabis use before TRS date | 846 (37.8) | 751 (88.8)                                   |
| Yes                    | 1393 (62.2)                 | 1086 (78.0)                                   |
| **The Health of the Nation Outcome Scale (HoNOS)** |                       |                                              |
| Behaviour and symptoms |                              |                                              |
| Overactive, aggressive behaviour (26.80% missing) | 749 (45.7) | 612 (81.7)                                   |
Table 1 (continued)

| Sample characteristics                                      | Total: n (% of total sample) | Prescribed clozapine: n (% per characteristic) |
|--------------------------------------------------------------|------------------------------|-----------------------------------------------|
| Problem                                                      | 889 (54.3)                   | 668 (75.1)                                   |
| Hallucinations and delusions (27.0% missing)                 |                              |                                               |
| Not a problem                                                | 309 (18.9)                   | 237 (76.7)                                   |
| Problem                                                      | 1325 (98.1)                  | 1041 (78.6)                                  |
| Depressed mood (27.1% missing)                              |                              |                                               |
| Not a problem                                                | 789 (48.3)                   | 611 (77.4)                                   |
| Problem                                                      | 843 (51.7)                   | 665 (78.9)                                   |
| Non-accidental self-injury (26.3% missing)                   |                              |                                               |
| Not a problem                                                | 1430 (87.4)                  | 1109 (77.6)                                  |
| Problem                                                      | 206 (12.6)                   | 169 (82.1)                                   |
| Problem drinking or drug-taking (27.4% missing)              |                              |                                               |
| Not a problem                                                | 1119 (68.9)                  | 890 (79.5)                                   |
| Problem                                                      | 506 (31.1)                   | 383 (75.7)                                   |
| Cognitive problems (27.1% missing)                           |                              |                                               |
| Not a problem                                                | 819 (50.1)                   | 639 (78.0)                                   |
| Problem                                                      | 815 (49.9)                   | 637 (78.2)                                   |
| Physical illness or disability problems (27.1% missing)b     |                              |                                               |
| Not a problem                                                | 966 (59.1)                   | 770 (79.7)                                   |
| Problem                                                      | 667 (40.9)                   | 505 (75.7)                                   |
| Impairment, social and functional status (HoNOS)             |                              |                                               |
| Social relationships (27.4% missing)                         |                              |                                               |
| Not a problem                                                | 511 (31.4)                   | 406 (79.5)                                   |
| Problem                                                      | 1115 (68.6)                  | 866 (77.7)                                   |
| Activities of daily living (ADLs) (27.6% missing)            |                              |                                               |
| Not a problem                                                | 613 (37.8)                   | 480 (78.3)                                   |
| Problem                                                      | 1009 (62.2)                  | 791 (78.4)                                   |
| Living conditions (29.6% missing)                            |                              |                                               |
| Not a problem                                                | 923 (58.6)                   | 741 (80.3)                                   |
| Problem                                                      | 653 (41.4)                   | 497 (76.1)                                   |
| Occupational and recreational activities (29.2% missing)     |                              |                                               |
| Not a problem                                                | 618 (39.0)                   | 488 (79.0)                                   |
| Problems                                                     | 967 (61.0)                   | 757 (78.3)                                   |
| Evidence of neutropenia or BEN                               |                              |                                               |
| No                                                           | 2078 (92.8)                  | 1712 (82.4)                                  |
| Yes                                                          | 161 (7.2)                    | 125 (77.6)                                   |
| Service-use                                                  |                              |                                               |
| Number of days of face-to-face contact with SLaM services in the 3 months before TRS date (Md 5, IQR 2–9, range 0–91) |                              |                                               |
| 0                                                            | 294 (13.1)                   | 267 (90.8)                                   |
| 1–7                                                          | 1235 (55.2)                  | 1014 (82.1)                                  |
| 8–14                                                         | 462 (20.6)                   | 366 (79.2)                                   |
| 15 and above                                                 | 248 (11.1)                   | 190 (76.6)                                   |
| Number of SLaM days in hospitalisation the 3 months before TRS date (Md 0, IQR 0–44, range 0–91) |                              |                                               |
| 0                                                            | 1152 (51.5)                  | 1003 (87.1)                                  |
| 1–29                                                         | 401 (17.9)                   | 289 (72.1)                                   |
| 30–59                                                        | 216 (9.7)                    | 166 (76.9)                                   |
| 60 and above                                                 | 470 (21.0)                   | 379 (80.6)                                   |
It was also observed that neutropenia was not associated with treatment with clozapine; neither in a crude model (OR = 0.74, 95% CI [0.50, 1.09], \( p = 0.132 \)), nor in the fully adjusted model (aOR = 0.82, 95% CI [0.51, 1.31], \( p = 0.415 \)).

Furthermore, people who had more than 30 days of hospitalisation, in the 3 months before the date they met proxy criteria for TRS, were more likely to be treated with clozapine (aOR30–59 days = 1.78, 95% CI [1.15, 2.75], \( p = 0.010 \); aOR60–90 days = 2.23, 95% CI [1.55, 3.20], \( p < 0.001 \)), than those who were not hospitalised (results not shown in tables). Those who were admitted under the MHA, at any point before TRS date, were less likely to receive clozapine. This was observed for all types of detentions: hospitalisation initiated by clinical staff (aOR = 0.23, 95% CI [0.16, 0.33], \( p < 0.001 \)), police conveying to a place of safety (aOR = 0.56, 95% CI [0.41, 0.75], \( p < 0.001 \)), and forensic detention (aOR = 0.44, 95% CI [0.27, 0.71], \( p = 0.001 \)).

### Discussion

We investigated potential ethnic differences in treatment with clozapine in a cohort of people with treatment-resistant schizophrenia. The results show that people of any Black background are less likely to receive clozapine than their White British counterparts. The differences were observed when controlling for other sociodemographic information, psychiatric comorbidities, substance misuse, evidence of neutropenia (including benign ethnic neutropenia), as well as frequency and type of service-use. No differences in clozapine treatment rates were observed between White British and people of any Asian background, Other White ethnicity, or any Other ethnicity.

Our results are consistent with the majority of studies, which report that minoritised ethnic people, particularly people from a Black background, are less likely to receive clozapine, the drug of choice for TRS [7, 20–23]. Our findings differ from a couple of studies [26, 27], but we used a cohort of people with TRS (which minimises confounding by indication) [26], and we have a much larger sample (which confers greater statistical power) [26, 27].

In this study, there were ethnic disparities in evidence of neutropenia (including benign ethnic neutropenia) confirming the greater prevalence of this condition among Black people [41]. The presence of neutropenia did not account for the ethnic differences in clozapine prescribing. This finding may be related to the fact that we measured mild neutropenia and not only severe neutropenia (< 1.5 × 10^9/L). Thus, mild neutropenia, as well as benign ethnic neutropenia, should not prevent treatment with clozapine. This is in line with the recommended guidelines [28, 41].

Minoritised ethnic people more frequently received involuntary care via the use of the MHA. Higher detention rates are observed in multiple previous studies [6, 42] and may suggest more constrained relationships with health services [43]. Detention under the MHA could be associated with medical non-adherence, and this can be a barrier to clozapine treatment given the need for frequent monitoring [29, 44]. Thus, interventions may be needed to improve engagement among people who were detained under the MHA. Future research could investigate if such interventions result in better illness management and more treatment with clozapine. This might be effective if illness-related non-compliance with blood tests was the reason for non-prescription, but if people are, or were, detained on the MHA, they could and should receive this evidence-based recommended treatment.

The mechanisms that led to the reduced likelihood of Black people being treated with clozapine are not fully understood in this study. Disparities in physical health, not measured in the study, could be related to the observed inequalities. For instance, diabetes, hypertension and cardiovascular disease seem to be more prevalent among Black communities than White British people [45–47]. The potential impact of clozapine on these conditions may discourage...
Table 2  Demographic and clinical characteristics among ethnic groups with treatment-resistant schizophrenia

| Sample characteristics | White British n (%) | Black Caribbean n (%) | Black British/other Black background n (%) | Black African n (%) | Other White background n (%) | Other ethnicity n (%) | Asian British/other Asian background n (%) | South Asian n (%) | p value |
|------------------------|---------------------|-----------------------|------------------------------------------|---------------------|-----------------------------|----------------------|-------------------------------------------|-----------------|--------|
| Sociodemographic factors |                     |                       |                                          |                     |                             |                      |                                           |                 |        |
| Gender—women           | 250 (34.8)          | 143 (36.6)            | 119 (32.1)                               | 147 (41.5)          | 49 (32.7)                   | 35 (32.1)            | 32 (38.1)                                | 26 (42.6) | $\chi^2(7) = 10.44, p=0.165$ |
| Age: $M$ (SD)          | 43.6 (13.2)         | 44.0 (11.9)           | 36.1 (10.1)                              | 37.4 (11.7)         | 41.0 (13.6)                 | 37.5 (12.0)         | 41.8 (13.3)                              | 42.2 (12.6) | $F(7) = 22.54, p<0.001$ |
| Ever homeless before TRS date | 49 (6.8)           | 35 (9.0)              | 45 (12.3)                                | 45 (12.9)           | 23 (15.5)                   | 10 (9.2)             | <10%                                      | <5%            | $\chi^2(7) = 23.19, p=0.002$ |
| Neighbourhood deprivation score: $M$ (SD) | 30.5 (9.9)          | 32.7 (8.6)            | 32.2 (8.6)                               | 33.0 (8.7)          | 30.8 (10.0)                 | 32.0 (8.2)          | 31.3 (8.9)                               | 29.0 (8.6) | $F(7) = 4.38, p<0.001$ |
| Primary diagnosis      |                     |                       |                                          |                     |                             |                      |                                           |                 | $\chi^2(14) = 31.06, p=0.005$ |
| Schizophrenia          | 573 (79.7)          | 307 (78.5)            | 294 (79.3)                               | 261 (73.7)          | 120 (80.0)                  | 82 (75.2)           | 62 (74.8)                                | 55 (90.2) |        |
| Schizoaffective disorder | 125 (17.4)         | 76 (19.4)             | 65 (17.5)                                | 73 (20.6)           | 26 (17.3)                   | 22 (20.2)           | 19 (22.6)                                | <10%          |        |
| Other prolonged psychosis | 94 (13.1)          | 23 (5.9)              | 22 (5.9)                                 | 34 (9.6)            | 18 (12.0)                   | 11 (10.1)           | 10 (11.9)                                | <10%          |        |
| Psychiatric comorbidities |                     |                       |                                          |                     |                             |                      |                                           |                 |        |
| Developmental disorders | 48 (6.7)           | 27 (6.9)              | 33 (8.9)                                 | 23 (6.5)            | 13 (8.7)                    | <10%                | <5%                                       | <5%            | $\chi^2(7) = 6.18, p=0.519$ |
| Anxiety-related disorders | 50 (7.0)           | <5%                   | 17 (4.6)                                 | 15 (4.2)            | 11 (7.3)                    | <10%                | <10%                                      | <5%            | $\chi^2(7) = 13.82, p=0.054$ |
| Bipolar disorder       | 106 (14.7)          | 56 (14.3)             | 60 (16.2)                                | 68 (19.2)           | 23 (15.3)                   | 17 (15.6)           | <10%                                      | 10 (16.4)    | $\chi^2(7) = 6.89, p=0.441$ |
| Depression or other mood disorders (excl. bipolar) | 132 (18.4)          | 43 (11.0)             | 61 (16.4)                                | 55 (15.5)           | 32 (21.3)                   | 10 (9.2)            | 11 (13.1)                                | <10%          | $\chi^2(7) = 19.72, p=0.006$ |
| Personality disorder   | 123 (17.1)          | 40 (10.2)             | 45 (12.1)                                | 29 (8.2)            | 22 (14.7)                   | <10%                | <10%                                      | <10%          | $\chi^2(7) = 29.24, p<0.001$ |
| Substance misuse       |                     |                       |                                          |                     |                             |                      |                                           |                 |        |
| Any substance use-related disorder | 103 (14.3)        | 58 (14.8)             | 52 (14.0)                                | 34 (9.6)            | 21 (14.0)                   | <10%                | <10%                                      | <5%            | $\chi^2(7) = 17.27, p=0.016$ |
| Evidence of cannabis use before TRS date | 394 (54.8)          | 275 (70.3)            | 282 (76.0)                               | 219 (61.9)          | 89 (59.3)                   | 65 (59.6)           | 44 (52.4)                                | 25 (41.0)    | $\chi^2(7) = 73.83, p<0.001$ |
Table 2 (continued)

| Sample characteristics | White British n (%) | Black Caribbean n (%) | Black British/other Black background n (%) | Black African n (%) | Other White background n (%) | Other ethnicity n (%) | Asian British/other Asian background n (%) | South Asian n (%) | p value |
|------------------------|---------------------|-----------------------|---------------------------------------------|--------------------|-----------------------------|---------------------|---------------------------------------------|------------------|---------|
| The Health of the Nation Outcome Scale (HoNOS) | | | | | | | | |
| Behaviour and symptoms | | | | | | | | |
| Overactive, aggressive behaviour | 250 (52.1) | 152 (51.4) | 167 (58.4) | 164 (55.0) | 51 (54.3) | 48 (59.3) | 33 (55.9) | 24 (54.6) | $\chi^2(7) = 4.85$, $p=0.679$ |
| Non-accidental self-injury | 81 (16.9) | 22 (7.4) | 33 (11.6) | 23 (7.7) | 17 (18.1) | 12 (14.8) | 10 (17.0) | < 20% | $\chi^2(7) = 27.04$, $p<0.001$ |
| Problem with drinking or drug-taking | 155 (32.4) | 91 (30.9) | 102 (36.4) | 81 (27.5) | 28 (30.11) | 26 (32.1) | 13 (22.0) | 10 (22.7) | $\chi^2(7) = 9.71$, $p=0.205$ |
| Hallucinations and delusions | 389 (81.2) | 224 (75.7) | 228 (79.7) | 247 (83.7) | 73 (77.7) | 73 (90.1) | 52 (88.1) | 39 (88.6) | $\chi^2(7) = 15.93$, $p=0.026$ |
| Depressed mood | 274 (57.2) | 135 (45.6) | 130 (45.8) | 131 (44.4) | 54 (57.5) | 61 (75.3) | 39 (66.1) | 19 (43.2) | $\chi^2(7) = 45.98$, $p<0.001$ |
| Impairment, social and functional status | | | | | | | | |
| Cognitive problems | 242 (50.6) | 150 (50.9) | 140 (49.0) | 133 (44.8) | 48 (51.1) | 44 (54.3) | 37 (62.7) | 21 (47.7) | $\chi^2(7) = 8.06$, $p=0.327$ |
| Physical illness or disability problems | 218 (45.8) | 129 (43.7) | 97 (33.9) | 115 (38.6) | 42 (44.7) | 23 (28.4) | 25 (42.4) | 18 (40.9) | $\chi^2(7) = 17.98$, $p=0.012$ |
| Social relationships | 327 (68.6) | 183 (62.2) | 200 (70.7) | 213 (72.2) | 63 (67.7) | 55 (67.9) | 42 (71.2) | 32 (72.7) | $\chi^2(7) = 8.43$, $p=0.296$ |
| Activities of daily living | 318 (66.5) | 186 (63.5) | 177 (62.3) | 170 (58.2) | 55 (59.1) | 48 (60.0) | 32 (55.2) | 23 (52.3) | $\chi^2(7) = 9.56$, $p=0.214$ |
| Living conditions | 178 (38.0) | 120 (42.7) | 125 (46.1) | 123 (43.0) | 40 (44.9) | 30 (38.0) | 28 (48.3) | < 25% | $\chi^2(7) = 14.69$, $p=0.040$ |
| Occupational and recreational activities | 278 (58.7) | 174 (61.7) | 171 (63.6) | 174 (60.2) | 61 (67.8) | 52 (65.0) | 37 (63.8) | 20 (46.5) | $\chi^2(7) = 8.24$, $p=0.312$ |
| Evidence of neutropenia or BEN | 15 (2.1) | 29 (7.4) | 46 (12.4) | 54 (15.3) | < 5% | < 10% | < 5% | < 5% | $\chi^2(7) = 86.34$, $p<0.001$ |
| Service-use | | | | | | | | |
| Number of days of face-to-face contact with SLaM services in the 3 months before TRS date | | | | | | | | |
| 0 | 92 (12.8) | 58 (14.8) | 51 (13.8) | 45 (12.7) | 24 (16.0) | < 10% | < 10% | < 15% | $\chi^2(21) = 20.83$, $p=0.469$ |
clinicians and service-users from choosing this treatment [48], even though there may not be safe alternatives to clozapine, given that other antipsychotics with high efficacy, such as olanzapine, or zotepine, also have metabolic side-effects [49, 50]. Nonetheless, in a previous study in the USA, diabetes and cardiovascular illness had little association with clozapine treatment, and ethnic disparities persisted when controlling for those [24].

Having that limitation in mind, the findings of this study contribute to the accumulation of evidence regarding ethnic inequalities in care in the UK [2, 5, 8]. This evidence may indicate a pattern of structural racism in healthcare, which could be related to unconscious bias [51–53]. In the USA, clinicians’ unconscious bias was associated with clinicians spending less time speaking with African–Americans, perceived lower warmth and friendliness, and lower quality of care [54]. An explanatory model proposes that negative stereotypes regarding ethnic minorities can arouse negative emotions in clinical staff, which then lead to clinical actions of neglect or harm (e.g., unnecessary invasive care) [52]. Notwithstanding, whether these systemic biases are prevalent in the UK, and their potential impact in healthcare, needs further study.

### Strengths and limitations

We used data from a large mental healthcare provider in the UK in an area whose population is very diverse (about 58.5% of residents are of an ethnic minority background) [55]. The service-users in the study should be representative of the study’s population, given the free access to care. The study’s 11-year observation window allowed identifying a large sample of people with TRS and controlling for multiple confounders. Moreover, one of these was evidence of neutropenia, which has been reported as the potential major driver of ethnic disparities in clozapine treatment.

Some limitations include the use of an algorithm to identify TRS. The rules of the tested algorithms are not as fine-grained as those used to develop the manually coded gold-standard dataset. Moreover, it is likely that we are missing cases of TRS where there was no prescription of clozapine, given that we prioritised the precision of the algorithm. Unlike other cohort studies, a proportion of service-users were coded as having the outcome at the point of cohort entry, due to being treated with clozapine. Establishing a TRS cohort whose ascertainment criteria did not include clozapine would substantially reduce the sample size and compromise the achievement of this study aims. Given the focus on ethnicity, we believe the study’s cross-sectional design does not affect the reliability of the findings. There was substantial missing information in the HoNOS assessment, and preliminary analyses revealed that people whose TRS date corresponds to the date of clozapine or ZTAS registration had a higher proportion of missing data. Furthermore, we did not evaluate service-users preferences of care and/or rejection of treatment with clozapine [29], nor other potential individual barriers that could be associated

### Table 2 (continued)

| Sample characteristics | White British n (%) | Black Caribbean n (%) | Black British/other Black background n (%) | Black African n (%) | Other White background n (%) | Other ethnicity n (%) | Asian British/other Asian background n (%) | South Asian n (%) | p value |
|------------------------|---------------------|-----------------------|-------------------------------------------|---------------------|-----------------------------|----------------------|-------------------------------------------|------------------|---------|
| 15 and above           | 87 (12.1)           | 37 (9.5)              | 36 (9.7)                                   | 43 (12.2)           | 19 (12.7)                   | 10 (9.2)             | <15%                                      | <15%             |

Number of SLaM days in hospitalisation in the 3 months before TRS date

|                          | 0                   | 1–29                  | 30–59                                    | 60 and above        |
|--------------------------|---------------------|-----------------------|------------------------------------------|---------------------|
| 0                        | 425 (59.1)          | 199 (50.9)            | 163 (43.9)                               | 148 (41.8)          |
| 1–29                     | 119 (16.6)          | 59 (15.1)             | 68 (18.3)                                | 72 (20.3)           |
| 30–59                    | 64 (8.9)            | 41 (10.5)             | 40 (10.8)                                | 44 (12.4)           |
| 60 and above             | 111 (15.4)          | 92 (23.5)             | 100 (27.0)                               | 90 (25.4)           |

Involuntary care under the MHA before TRS date

|                          | Part 2—civil detention | Police detention | Part 3—forensic detention |
|--------------------------|-------------------------|------------------|---------------------------|
|                          | 271 (37.7)              | 81 (11.3)        | 37 (5.2)                  |
|                          | 209 (53.5)              | 67 (17.1)        | 44 (11.3)                 |
|                          | 218 (58.8)              | 71 (19.1)        | 46 (12.4)                 |
|                          | 239 (67.5)              | 91 (25.7)        | 34 (9.6)                  |
|                          | 71 (47.3)               | 20 (13.3)        | 14 (9.3)                  |
|                          | 58 (53.2)               | 17 (15.6)        | <5%                       |
|                          | 45 (53.6)               | <10%             | <5%                       |

Note: In cells where the number of people was smaller than 10, we present the closest % in multiples of 5
| Ethnicity                                      | Odds ratio [95% CI] | p value |
|----------------------------------------------|---------------------|---------|
| **Crude model (N=2239)**                     |                     |         |
| White British                                | Ref                 |         |
| Black Caribbean                              | 0.50 [0.36, 0.70]   | <0.001  |
| Black British/other Black background         | 0.57 [0.41, 0.80]   | 0.001   |
| Black African                                | 0.44 [0.32, 0.61]   | <0.001  |
| Other White background                       | 0.84 [0.51, 1.39]   | 0.506   |
| Other ethnic background                      | 0.78 [0.44, 1.38]   | 0.397   |
| Asian British/other Asian background         | 0.67 [0.37, 1.21]   | 0.185   |
| South Asian                                  | 1.12 [0.49, 2.53]   | 0.789   |
| **Adjusted for sociodemographic factors**    | (N=2188)            |         |
| White British                                | Ref                 |         |
| Black Caribbean                              | 0.53 [0.38, 0.74]   | <0.001  |
| Black British/other Black background         | 0.49 [0.33, 0.70]   | <0.001  |
| Black African                                | 0.38 [0.27, 0.55]   | <0.001  |
| Other White background                       | 0.86 [0.51, 1.47]   | 0.591   |
| Other ethnic background                      | 0.64 [0.36, 1.15]   | 0.135   |
| Asian British/other Asian background         | 0.58 [0.32, 1.08]   | 0.088   |
| South Asian                                  | 1.10 [0.45, 2.67]   | 0.833   |
| **Adjusted for diagnosis and comorbidities** | (N=2239)            |         |
| White British                                | Ref                 |         |
| Black Caribbean                              | 0.45 [0.32, 0.64]   | <0.001  |
| Black British/other Black background         | 0.55 [0.39, 0.78]   | 0.001   |
| Black African                                | 0.42 [0.31, 0.61]   | <0.001  |
| Other White background                       | 0.86 [0.51, 1.44]   | 0.571   |
| Other ethnic background                      | 0.72 [0.41, 1.29]   | 0.274   |
| Asian British/other Asian background         | 0.59 [0.31, 1.08]   | 0.092   |
| South Asian                                  | 1.05 [0.46, 2.41]   | 0.913   |
| **Adjusted for substance misuse**            | (N=2239)            |         |
| White British                                | Ref                 |         |
| Black Caribbean                              | 0.53 [0.38, 0.75]   | <0.001  |
| Black British/other Black background         | 0.63 [0.45, 0.89]   | 0.009   |
| Black African                                | 0.44 [0.31, 0.61]   | <0.001  |
| Other White background                       | 0.85 [0.52, 1.43]   | 0.555   |
| Other ethnic background                      | 0.76 [0.43, 1.34]   | 0.341   |
| Asian British/other Asian background         | 0.61 [0.34, 1.14]   | 0.121   |
| South Asian                                  | 0.91 [0.40, 2.09]   | 0.833   |
| **Adjusted for behaviour and symptoms (HoNOS)** | (N=1616)            |         |
| White British                                | Ref                 |         |
| Black Caribbean                              | 0.63 [0.44, 0.91]   | 0.013   |
| Black British/other Black background         | 0.74 [0.51, 1.08]   | 0.125   |
| Black African                                | 0.57 [0.40, 0.82]   | 0.002   |
| Other White background                       | 0.81 [0.46, 1.41]   | 0.453   |
| Other ethnic background                      | 0.84 [0.46, 1.53]   | 0.569   |
| Asian British/other Asian background         | 0.71 [0.36, 1.37]   | 0.305   |
| South Asian                                  | 1.06 [0.45, 2.47]   | 0.898   |
| **Adjusted for impairment, social and functional problems (HoNOS)** | (N=1537)            |         |
| White British                                | Ref                 |         |
| Black Caribbean                              | 0.62 [0.43, 0.90]   | 0.012   |
| Black British/other Black background         | 0.69 [0.48, 1.03]   | 0.067   |
| Black African                                | 0.56 [0.39, 0.81]   | 0.002   |
| Other White background                       | 0.85 [0.47, 1.52]   | 0.576   |
with refusal of clozapine treatment, including the perception of stigma related to clozapine treatment, severe economic deprivation, which could limit access to transportation and participation on the frequent blood monitoring regime, or fear the side-effects of clozapine (e.g., weight gain) [49]. Finally, a relevant limitation is the non-inclusion of information regarding physical conditions that could affect the decision to prescribe clozapine [45]. The impact of potential bias due to the mentioned drawbacks cannot be fully estimated and future studies should address these limitations.

### Table 3 (continued)

| Ethnicity                          | Odds ratio [95% CI] | p value |
|------------------------------------|---------------------|---------|
| Other ethnic background            | 0.74 [0.40, 1.36]   | 0.332   |
| Asian British/other Asian background | 0.71 [0.36, 1.38] | 0.314   |
| South Asian                        | 1.17 [0.47, 2.89]   | 0.728   |
| Adjusted for neutropenia or benign ethnic neutropenia (N=2239)                                      |
| White British                      | Ref                 |         |
| Black Caribbean                    | 0.50 [0.36, 0.69]   | < 0.001 |
| Black British/other Black background | 0.58 [0.41, 0.81] | 0.006   |
| Black African                      | 0.45 [0.33, 0.63]   | < 0.001 |
| Other White background             | 0.84 [0.52, 1.40]   | 0.511   |
| Other ethnic background            | 0.79 [0.45, 1.38]   | 0.407   |
| Asian British/other Asian background | 0.67 [0.37, 1.21] | 0.187   |
| South Asian                        | 1.12 [0.49, 2.52]   | 0.793   |
| Adjusted for service use\(^a\) (N=2239)                                      |
| White British                      | Ref                 |         |
| Black Caribbean                    | 0.61 [0.43, 0.87]   | 0.006   |
| Black British/other Black background | 0.80 [0.56, 1.15] | 0.233   |
| Black African                      | 0.71 [0.50, 1.00]   | 0.055   |
| Other White background             | 1.05 [0.61, 1.80]   | 0.846   |
| Other ethnic background            | 1.03 [0.57, 1.87]   | 0.922   |
| Asian British/other Asian background | 0.78 [0.41, 1.46] | 0.435   |
| South Asian                        | 1.26 [0.53, 3.01]   | 0.593   |
| Fully adjusted without HoNOS\(^g\) (N=2188)                                      |
| White British                      | Ref                 |         |
| Black Caribbean                    | 0.64 [0.43, 0.93]   | 0.019   |
| Black British/other Black background | 0.61 [0.41, 0.91] | 0.016   |
| Black African                      | 0.49 [0.33, 0.74]   | 0.001   |
| Other White background             | 1.03 [0.58, 1.86]   | 0.904   |
| Other ethnic background            | 0.65 [0.35, 1.23]   | 0.472   |
| Asian British/other Asian background | 0.62 [0.32, 1.23] | 0.173   |
| South Asian                        | 1.09 [0.42, 2.85]   | 0.845   |

\(^a\)Gender, age, homelessness and neighbourhood level of deprivation  
\(^b\)Main schizophrenia spectrum diagnosis and comorbid diagnoses (developmental, anxiety, bipolar, depressive, and personality disorders)  
\(^c\)Substance use-related disorder and cannabis use  
\(^d\)HoNOS items of behaviours and symptoms (overactive, self-injury, drinking or drug-taking, hallucinations, and depressed mood)  
\(^e\)HoNOS items of social and functional problems (cognitive, physical, relationships, activities of daily living, living conditions, and occupational problems)  
\(^f\)Number of days with face-to-face contact with services and in hospitalisation in the 3 months before TRS date, and involuntary care under the MHA  
\(^g\)All the variables on mentioned on a, b, c, and f. HoNOS variables (included under d and e) were excluded due to a large volume of missing data and its consequences to the statistical power of the analyses
Conclusions

This study reveals that Black service-users with TRS have half the odds of being treated the recommended treatment, clozapine, after accounting for several possible confounders. Thus, further research is needed to understand the drivers of ethnic inequities in access to clozapine. Reduced odds of having treatment with clozapine may place Black people at greater risk of negative outcomes, such as higher hospital readmission [15] and mortality [16].

Neutropenia, a potential driver of ethnic inequalities [29], was not associated with clozapine treatment in this study. Also, there is evidence, from this and previous studies [6–8, 15, 42, 56], to suggest that Black people with psychosis may be facing unequal care across several stages of illness care trajectory—from referral to secondary care to the third-line antipsychotic treatment, clozapine. Additionally, the negative relation between lifetime detention under the MHA and treatment with clozapine may suggest a vicious circle of inaction—neither overengagement with services and not receiving the recommended care [43]. Optimal use of healthcare can be limited due to several factors [57], and to decrease healthcare inequalities, interventions taking a systemic approach should be implemented. Furthermore, it is possible that clinical decisions are being affected by unconscious bias. Actions to challenge interpersonal, institutional and structural bias in mental healthcare are recommended [53, 58, 59].

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00127-022-02257-3.

Acknowledgements The authors wish to acknowledge the contribution of Emma Francis, Isobel Ridler, and Anna Morris to the ascertainment of TRS in the gold-standard, manually coded, dataset.

Funding This work utilised the Clinical Record Interactive Search (CRIS) platform, funded and developed by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. RP received support from a NIHR Advanced Fellowship (NIHR301690), a Medical Research Council (MRC) Health Data Research UK Fellowship (MR/S003118/1) and a Starter Grant for Clinical Lecturers (SGL015/1020) supported by the Academy of Medical Sciences, The Wellcome Trust, MRC, British Heart Foundation, Arthritis Research UK, the Royal College of Physicians and Diabetes UK. ID is supported by the NIHR Clinician Science Fellowship award (CS-2018-18-ST2-014), received support from a MRC Clinical Research Training Fellowship (MR/L017105/1) and a Psychiatry Research Trust Peggy Pollak Research Fellowship in Developmental Psychiatry. The views expressed are those of the authors and not those of the funding organisations mentioned.

Declarations

Conflict of interest All authors completed the ICMJE uniform disclosure. During the conduction of the study, DFdF, GKS, and RH reported receiving funds from the NIHR Maudsley Biomedical Research Centre. For other activities outside the submitted work: DFdF reported research funding from the UK Department of Health and Social Care, Janssen Research & Development LLC, and H. Lundbeck A/S; GKS received research funding from Janssen Research & Development LLC and H. Lundbeck A/S; RP reports grants from the NIHR, the Medical Research Council, the Academy of Medical Sciences, and Janssen-Cilag, and personal fees from Induction Healthcare and from Holmusk; JHM received research funding from H. Lundbeck A/S and the Medical Research Council; and RH received research funding from Janssen Research & Development LLC, H. Lundbeck A/S, Medical Research Council and from the UK Department of Health and Social Care.

Ethics approval CRIS dataset received approval from the Oxford C Research Ethics Committee (18/SC/0372). All projects using the CRIS dataset are submitted for approval to an oversight committee led by service-users.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Meghani SH, Byun E, Gallagher RM (2012) Time to take stock: a meta-analysis and systematic review of analgesic treatment disparities for pain in the United States. Pain Med 13:150–174. https://doi.org/10.1111/j.1526-4637.2011.01310.x
2. Pinder RJ, Ferguson J, Möller H (2016) Minority ethnicity patient satisfaction and experience: results of the National Cancer Patient Experience Survey in England. BMJ Open 6:e011938. https://doi.org/10.1136/bmjopen-2016-011938
3. Henderson J, Gao H, Redshaw M (2013) Experiencing maternity care: the care received and perceptions of women from different ethnic groups. BMC Pregnancy Childb 13:196. https://doi.org/10.1186/1471-2393-13-196
4. McManus S, Bebbington P, Jenkins R, Brugha T (2016) Mental health and wellbeing in England: adult psychiatric morbidity survey 2014. In: NHS Digit. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/556596/apms-2014-full-rpt.pdf
5. Chui Z, Gazzard B, MacCrimmon S et al (2020) Inequalities in referral pathways for young people accessing secondary mental health services in south east London. Eur Child Adolesc Psychiatry. https://doi.org/10.1007/s00787-020-01603-7
6. Halvorsrud K, Nazroo J, Otis M et al (2018) Ethnic inequalities and pathways to care in psychosis in England: a systematic review and meta-analysis. BMC Med 16:223. https://doi.org/10.1186/s12916-018-1201-9
7. Das-Munshi J, Bhugra D, Crawford MJ (2018) Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study. BMC Med 16:1–10. https://doi.org/10.1186/s12916-018-1035-5
8. Morris RM, Sellwood W, Edge D et al (2020) Ethnicity and impact on the receipt of cognitive–behavioural therapy in people with psychosis or bipolar disorder: an English cohort study. BMJ Open 10:e034913. https://doi.org/10.1136/bmjopen-2019-034913
9. NICE (2014) Psychosis and schizophrenia in adults: prevention and management. https://www.nice.org.uk/guidance/cg178
10. Siskind D, Orr S, Sinha S et al (2021) Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. https://doi.org/10.1192/bjp.2021.61
11. Howes OD, McCutcheon R, Agid O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174:216–229. https://doi.org/10.1176/appi.ajp.2016.16050503
12. Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209:385–392. https://doi.org/10.1192/bjp.bp.115.177261
13. Lewis SW, Barnes TRE, Davies L et al (2005) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32:715–723. https://doi.org/10.1093/schbul/sby067
14. Land R, Siskind D, McArdle P et al (2017) The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 135:296–309. https://doi.org/10.1111/acs.12700
15. Kesservani I, Kadra G, Downs J et al (2019) Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine. J Psychopharmacol 33:449–458. https://doi.org/10.1177/0269881118118817387
16. Cho J, Hayes RD, Jewell A et al (2018) Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand. https://doi.org/10.1111/acps.12989
17. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ et al (2016) Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull 43:315–329. https://doi.org/10.1093/schbul/sby052
18. Copeland LA, Zeber JE, Valenstein M, Blow FC (2003) Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry 160:1817–1822. https://doi.org/10.1176/appi.ajp.160.10.1817
19. Mallinger JB, Fisher SG, Brown T, Lamberti JS (2006) Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 57:133–136. https://doi.org/10.1176/appi.ps.57.1.133
20. Williams JC, Harowitz J, Glover J et al (2020) Systematic review of racial disparities in clozapine prescribing. Schizophr Res 224:11–18. https://doi.org/10.1016/j.schres.2020.07.023
21. Beck K, McCutcheon R, Stephenson L et al (2019) Prevalence of treatment-resistant psychoses in the community: a naturalistic study. J Psychopharmacol. https://doi.org/10.1176/jpp.2019.85595
22. Kelly DL, Dixon LB, Kreyenbuhl JA et al (2006) Clozapine utilization and outcomes by race in a public mental health system: 1994–2000. J Clin Psychiatry 67:1404–1411. https://doi.org/10.4088/JCP.v67n0911
23. Kanno E, Rothbard AB (2002) Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 159:567–572. https://doi.org/10.1176/appi.ajp.159.4.567
24. Stroup TS, Gerhard T, Crystal S et al (2014) Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 65:186–192. https://doi.org/10.1176/appi.ps.201300180
25. Manuel JI, Essock SM, Wu Y et al (2012) Factors associated with initiation on clozapine and on other antipsychotics among medicare enrollees. Psychiatr Serv 63:1146–1149. https://doi.org/10.1176/appi.ps.201100435
26. Connolly A, Rogers P, Taylor D (2007) Antipsychotic prescribing quality and ethnicity—a study of hospitalized patients in south east London. J Psychopharmacol 21:191–197. https://doi.org/10.1177/0269881107065899
27. Lally J, Ajnakina O, Di Fori M et al (2016) Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 46:3231–3240. https://doi.org/10.1017/S0033291716002014
28. Mami P, Saravia N, Rogozea LM et al (2016) Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations. J Clin Psychiatry 77:e909–e916. https://doi.org/10.4088/JCP.15r10085
29. Farooq S, Choudry A, Cohen D et al (2019) Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJPsych Bull 43:8–16. https://doi.org/10.1192/bjp.2018.67
30. Myles N, Myles H, Xia S et al (2018) Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 138:101–109. https://doi.org/10.1111/acps.12898
31. Stewart R, Soremekun M, Perera G et al (2009) The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry 9:51. https://doi.org/10.1186/1471-244X-9-51
32. Perera G, Broadbent M, Callard F et al (2016) Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource. BMJ Open 6:1–22. https://doi.org/10.1136/bmjopen-2015-008721
33. CRIS NLP Service (2021) Library of production-ready applications, v1.6. https://www.maudsleybrc.nihr.ac.uk/facilities/clinical-record-interactive-search-cris/cris-natural-language-processing/
34. Jackson RG, Patel R, Jayatilleke N et al (2017) Natural language processing to extract symptoms of severe mental illness from clinical text: the Clinical Record Interactive Search Comprehensive Data Extraction (CRIS-CODE) project. BMJ Open 7:e012012. https://doi.org/10.1136/bmjopen-2016-012012
35. Kadra-Scalzo G, Freitas DF, Agbedjro D et al (submitted) Predicting treatment resistance in schizophrenia using clinical and demographic information: a predictor model using data from electronic health records. J Schizophrenia Res. https://doi.org/10.1177/1093128X211092906
36. Department for Communities and Local Government (2011) The Department for Communities and Local Government (2011) The English indices of deprivation 2010. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/6871/1871208.pdf
37. Patel R, Wilson R, Jackson R et al (2016) Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open 6:e009888. https://doi.org/10.1136/bmjopen-2015-009888
38. Wing JK, Curtis RH, Beevor AS (1999) Health of the Nation Outcome Scales (HoNOS). Br J Psychiatry 174:432–434. https://doi.org/10.1192/bjp.174.5.432
39. HM Government (1983) Mental Health Act 1983. http://www.legislation.gov.uk/ukpga/1983/20/contents
40. StataCorp (2017) Stata statistical software: release 15
41. Whiskey E, Olofinjana O, Taylor D (2011) The importance of the Mental Health Act legislation. gov.uk/ukpga/1983/20/contents
42. Barnett P, Mackay E, Matthews H et al (2019) Ethnic variations in compulsory detention under the Mental Health Act: a systematic
43. Lawrence V, McCombie C, Nikolakopoulos G, Morgan C (2021) Ethnicity and power in the mental health system: experiences of white British and black Caribbean people with psychosis. Epidemiol Psychiatr Sci 30:e12. https://doi.org/10.1017/S2045796020001043

44. Verdoux H, Quiles C, Bachmann CJ, Siskind D (2018) Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res 201:10–19. https://doi.org/10.1016/j.schres.2018.05.046

45. El-Sayed AM, Scarborough P, Galea S (2011) Ethnic inequalities in obesity among children and adults in the UK: a systematic review of the literature. Obes Rev 12:e516–e534. https://doi.org/10.1111/j.1467-789X.2010.00829.x

46. Lip GYH, Barnett AH, Bradbury A et al (2007) Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. J Hum Hypertens 21:183–211. https://doi.org/10.1038/sj.jhh.1002126

47. Nazroo JY, Falaschetti E, Pierce M, Primatesta P (2009) Ethnic inequalities in access to and outcomes of healthcare: analysis of the Health Survey for England. J Epidemiol Community Health 63:1022–1027. https://doi.org/10.1136/jech.2009.089409

48. Nemani KL, Greene MC, Ulloa M et al (2019) Clozapine, diabetes mellitus, cardiovascular risk and mortality: results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses 12:168–176. https://doi.org/10.3371/CSRP.KNMG.111717

49. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939–951. https://doi.org/10.1016/S0140-6736(19)31135-3

50. Fleschhacker WW, Siu CO, Bodén R et al (2013) Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 16:987–995. https://doi.org/10.1017/S1461145712001241

51. Cabinet Office (2018) Race disparity audit. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/686071/Revised_RDA_report_March_2018.pdf

52. Dovidio JF, Fiske ST (2012) Under the radar: how unexamined biases in decision-making processes in clinical interactions can contribute to health care disparities. Am J Public Health 102:945–952. https://doi.org/10.2105/AJPH.2011.300601

53. Nazroo JY, Bhui KS, Rhodes J (2020) Where next for understanding race/ethnic inequalities in severe mental illness? Structural, interpersonal and institutional racism. Sociol Health Illn 42:262–276. https://doi.org/10.1111/1467-9566.13001

54. Hall WJ, Chapman MV, Lee KM et al (2015) Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health 105:e60–e76. https://doi.org/10.2105/AJPH.2015.302903

55. ONS (Office for National Statistics) (2011) Nomis—official labour market statistics. https://www.nomisweb.co.uk/census/2011/ks201

56. Colling C, Evans L, Broadbent M et al (2017) Identification of the delivery of cognitive behavioural therapy for psychosis (CBTp) using a cross-sectional sample from electronic health records and open-text information in a large UK-based mental health case register. BMJ Open 7:1–10. https://doi.org/10.1136/bmjopen-2016-015297

57. Scheppers E (2006) Potential barriers to the use of health services among ethnic minorities: a review. Fam Pract 23:325–348. https://doi.org/10.1093/fampra/cmi13

58. RCPsych (Royal College of Psychiatrists) (2021) Six in ten Black, Asian and Minority Ethnic psychiatrists have experienced racism at work. https://www.rcpsych.ac.uk/news-and-features/latest-news/detail/2021/01/21/six-in-ten-black-asian-and-minority-ethnic-psychiatrists-have-experienced-racism-at-work

59. RCPsych (Royal College of Psychiatrists) (2021) RCPsych Equality Action Plan 2021–23. https://www.rcpsych.ac.uk/about-us/equality-diversity-and-inclusion/equality-action-plan